Replies to post #252 on Endocyte Inc fka ECYT

[grawsha]

"Aria bottom out at $2.15"
That company didn't have the strong pipeline, strong cash position and backing of analysts ECYT has.

"The once promising ovarian cancer Phase 3 trial was what makes ECYT price even at $30 "
No. It's the Lung cancer drug that caused the big move to $30. Friday's news was about Ovarian cancer drug.